250 related articles for article (PubMed ID: 15332276)
1. Molecular testing for detection of in vitro infectivity of plasma pools contaminated with B19 virus.
Bonvicini F; Gallinella G; Cricca M; Ambretti S; Delbarba S; Musiani M; Zerbini M
J Med Virol; 2004 Oct; 74(2):272-6. PubMed ID: 15332276
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay.
Kleinman SH; Glynn SA; Lee TH; Tobler L; Montalvo L; Todd D; Kiss JE; Shyamala V; Busch MP;
Transfusion; 2007 Oct; 47(10):1756-64. PubMed ID: 17880600
[TBL] [Abstract][Full Text] [Related]
3. Parvovirus B19 infection in pregnancy: quantitative viral DNA analysis using a kinetic fluorescence detection system (TaqMan PCR).
Knöll A; Louwen F; Kochanowski B; Plentz A; Stüssel J; Beckenlehner K; Jilg W; Modrow S
J Med Virol; 2002 Jun; 67(2):259-66. PubMed ID: 11992588
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of different assays for the detection of parvovirus B19 DNA in human plasma.
Baylis SA; Shah N; Minor PD
J Virol Methods; 2004 Oct; 121(1):7-16. PubMed ID: 15350727
[TBL] [Abstract][Full Text] [Related]
5. Parvovirus B19 transmission by a high-purity factor VIII concentrate.
Wu CG; Mason B; Jong J; Erdman D; McKernan L; Oakley M; Soucie M; Evatt B; Yu MY
Transfusion; 2005 Jun; 45(6):1003-10. PubMed ID: 15935000
[TBL] [Abstract][Full Text] [Related]
6. Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing.
Geng Y; Wu CG; Bhattacharyya SP; Tan D; Guo ZP; Yu MY
Transfusion; 2007 May; 47(5):883-9. PubMed ID: 17465954
[TBL] [Abstract][Full Text] [Related]
7. Effects of transfusion on human erythrovirus B19-susceptible or -infected pediatric recipients in a genotype 3-endemic area.
Parsyan A; Addo-Yobo E; Owusu-Ofori S; Akpene H; Sarkodie F; Allain JP
Transfusion; 2006 Sep; 46(9):1593-600. PubMed ID: 16965589
[TBL] [Abstract][Full Text] [Related]
8. Analysis of B19 virus contamination in plasma pools for manufacturing, by using a competitive polymerase chain reaction assay.
Gallinella G; Moretti E; Nardi G; Zuffi E; Bonvicini F; Bucci E; Musiani M; Zerbini M
Vox Sang; 2002 Nov; 83(4):324-31. PubMed ID: 12437519
[TBL] [Abstract][Full Text] [Related]
9. Evidence for persistence of human parvovirus B19 DNA in bone marrow.
Cassinotti P; Burtonboy G; Fopp M; Siegl G
J Med Virol; 1997 Nov; 53(3):229-32. PubMed ID: 9365887
[TBL] [Abstract][Full Text] [Related]
10. [Parvovirus B19 DNA testing in Polish blood donors, 2004-2010].
Grabarczyk P; Korzeniowska J; Liszewski G; Kalińska A; Sulkowska E; Krug-Janiak M; Kopacz A; Łetowska M; Brojer E
Przegl Epidemiol; 2012; 66(1):7-12. PubMed ID: 22708291
[TBL] [Abstract][Full Text] [Related]
11. Parvovirus B19 DNA in plasma pools and plasma derivatives.
Schmidt I; Blümel J; Seitz H; Willkommen H; Löwer J
Vox Sang; 2001 Nov; 81(4):228-35. PubMed ID: 11903998
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a new LightCycler reverse transcription-polymerase chain reaction infectivity assay for detection of human parvovirus B19 in dry-heat inactivation studies.
Prikhod'ko GG; Vasilyeva I; Reyes H; Wong S; Brown KE; Jameson T; Busby TF
Transfusion; 2005 Jun; 45(6):1011-9. PubMed ID: 15935001
[TBL] [Abstract][Full Text] [Related]
13. Prevention of iatrogenic transmission of B19 infection: different approaches to detect, remove or inactivate virus contamination.
Bonvicini F; Gallinella G; Gentilomi GA; Ambretti S; Musiani M; Zerbini M
Clin Lab; 2006; 52(5-6):263-8. PubMed ID: 16812953
[TBL] [Abstract][Full Text] [Related]
14. Development of an improved method of detection of infectious parvovirus B19.
Wong S; Brown KE
J Clin Virol; 2006 Apr; 35(4):407-13. PubMed ID: 16455300
[TBL] [Abstract][Full Text] [Related]
15. Human parvovirus B19 infection during pregnancy--value of modern molecular and serological diagnostics.
Enders M; Schalasta G; Baisch C; Weidner A; Pukkila L; Kaikkonen L; Lankinen H; Hedman L; Söderlund-Venermo M; Hedman K
J Clin Virol; 2006 Apr; 35(4):400-6. PubMed ID: 16332455
[TBL] [Abstract][Full Text] [Related]
16. Exposure of hematologic patients to parvovirus B19 as a contaminant of blood cell preparations and blood products.
Plentz A; Hahn J; Knöll A; Holler E; Jilg W; Modrow S
Transfusion; 2005 Nov; 45(11):1811-5. PubMed ID: 16271109
[TBL] [Abstract][Full Text] [Related]
17. Safety issues for plasma derivatives and benefit from NAT testing.
Willkommen H; Schmidt I; Löwer J
Biologicals; 1999 Dec; 27(4):325-31. PubMed ID: 10686059
[TBL] [Abstract][Full Text] [Related]
18. Maternal-fetal transmission of human parvovirus B19 genotype 3.
Candotti D; Danso K; Parsyan A; Dompreh A; Allain JP
J Infect Dis; 2006 Sep; 194(5):608-11. PubMed ID: 16897659
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of human erythrovirus B19 DNA in healthy Belgian blood donors and correlation with specific antibodies against structural and non-structural viral proteins.
Thomas I; Di Giambattista M; Gérard C; Mathys E; Hougardy V; Latour B; Branckaert T; Laub R
Vox Sang; 2003 May; 84(4):300-7. PubMed ID: 12757504
[TBL] [Abstract][Full Text] [Related]
20. Frequent detection of the parvoviruses, PARV4 and PARV5, in plasma from blood donors and symptomatic individuals.
Fryer JF; Delwart E; Hecht FM; Bernardin F; Jones MS; Shah N; Baylis SA
Transfusion; 2007 Jun; 47(6):1054-61. PubMed ID: 17524097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
